Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer - Annals of Oncology www.annalsofoncology.org/article/S092...
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-...
In PSMAfore, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged radiographic progression-free
survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate
cancer (mCRPC), with a f...
www.annalsofoncology.org
July 20, 2025 at 9:47 PM
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer - Annals of Oncology www.annalsofoncology.org/article/S092...
💫#ONCOnews💫
🚨BREAKING:
New Phase 3 PSMAfore data: [177Lu]Lu-PSMA-617 improves QoL, eases pain & lowers skeletal events in progressive mCRPC.
📊 A promising step forward in advanced prostate cancer care.
🔗 Read more: bit.ly/ONCOnews27M-1
#OncoAlert #OncEd #ProstateCancer #CancerResearch
🚨BREAKING:
New Phase 3 PSMAfore data: [177Lu]Lu-PSMA-617 improves QoL, eases pain & lowers skeletal events in progressive mCRPC.
📊 A promising step forward in advanced prostate cancer care.
🔗 Read more: bit.ly/ONCOnews27M-1
#OncoAlert #OncEd #ProstateCancer #CancerResearch
May 27, 2025 at 8:15 AM
💫#ONCOnews💫
🚨BREAKING:
New Phase 3 PSMAfore data: [177Lu]Lu-PSMA-617 improves QoL, eases pain & lowers skeletal events in progressive mCRPC.
📊 A promising step forward in advanced prostate cancer care.
🔗 Read more: bit.ly/ONCOnews27M-1
#OncoAlert #OncEd #ProstateCancer #CancerResearch
🚨BREAKING:
New Phase 3 PSMAfore data: [177Lu]Lu-PSMA-617 improves QoL, eases pain & lowers skeletal events in progressive mCRPC.
📊 A promising step forward in advanced prostate cancer care.
🔗 Read more: bit.ly/ONCOnews27M-1
#OncoAlert #OncEd #ProstateCancer #CancerResearch
PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC @mskcancercenter.bsky.social #pcsm #oncology
www.onclive.com/view/psmafor...
www.onclive.com/view/psmafor...
PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.
www.onclive.com
April 11, 2025 at 3:17 PM
PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC @mskcancercenter.bsky.social #pcsm #oncology
www.onclive.com/view/psmafor...
www.onclive.com/view/psmafor...
Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore
www.appliedclinicaltrialsonline.com/view/fda-app...
www.appliedclinicaltrialsonline.com/view/fda-app...
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.
www.appliedclinicaltrialsonline.com
March 29, 2025 at 7:19 AM
Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore
www.appliedclinicaltrialsonline.com/view/fda-app...
www.appliedclinicaltrialsonline.com/view/fda-app...
Intriguing CT DNA presented by Dr. Johann DeBono suggesting the value in assessing treatment response #PSMAfore #Lu-psma #mCRPC #ProstateCancer
Especially appreciate comparison to PSA50 responses given it’s already in clinic
It does make me wonder - what if we looked at PSA80? #GU25
Especially appreciate comparison to PSA50 responses given it’s already in clinic
It does make me wonder - what if we looked at PSA80? #GU25
February 13, 2025 at 7:49 PM
Intriguing CT DNA presented by Dr. Johann DeBono suggesting the value in assessing treatment response #PSMAfore #Lu-psma #mCRPC #ProstateCancer
Especially appreciate comparison to PSA50 responses given it’s already in clinic
It does make me wonder - what if we looked at PSA80? #GU25
Especially appreciate comparison to PSA50 responses given it’s already in clinic
It does make me wonder - what if we looked at PSA80? #GU25
Dr. Louise Emmett presents OS data from #Enzalutamide +/- #Lu-psma in 1st line mCRPC #ProstateCancer
Intriguing data to be sure but would have appreciated a built in cross-over given equivalent OS seen in #PSMAfore in 2nd line mCRPC when ARPI before or after Lu-psma #GU25 @ascocancer.bsky.social
Intriguing data to be sure but would have appreciated a built in cross-over given equivalent OS seen in #PSMAfore in 2nd line mCRPC when ARPI before or after Lu-psma #GU25 @ascocancer.bsky.social
February 13, 2025 at 7:32 PM
Dr. Louise Emmett presents OS data from #Enzalutamide +/- #Lu-psma in 1st line mCRPC #ProstateCancer
Intriguing data to be sure but would have appreciated a built in cross-over given equivalent OS seen in #PSMAfore in 2nd line mCRPC when ARPI before or after Lu-psma #GU25 @ascocancer.bsky.social
Intriguing data to be sure but would have appreciated a built in cross-over given equivalent OS seen in #PSMAfore in 2nd line mCRPC when ARPI before or after Lu-psma #GU25 @ascocancer.bsky.social